Jose S Reyes Torres, | |
400 Ave Fd Roosevelt, Ste 202, San Juan, PR 00918-2129 | |
(787) 621-3700 | |
Not Available |
Full Name | Jose S Reyes Torres |
---|---|
Gender | Male |
Speciality | Colorectal Surgery (proctology) |
Experience | 19 Years |
Location | 400 Ave Fd Roosevelt, San Juan, Puerto Rico |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1104028521 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | 17478 (Puerto Rico) | Secondary |
208C00000X | Colon & Rectal Surgery | 17478 (Puerto Rico) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Presbyterian Community Hosp | San juan, PR | Hospital |
Mailing Address | Practice Location Address |
---|---|
Jose S Reyes Torres, Po Box 2528, Guaynabo, PR 00970-2528 Ph: (787) 957-6262 | Jose S Reyes Torres, 400 Ave Fd Roosevelt, Ste 202, San Juan, PR 00918-2129 Ph: (787) 621-3700 |
News Archive
The Newshour has a transcript of a feature report on Dr. Atul Gawande's new book, "The Checklist Manifesto: How to Get Things Right," which "grew out of work he did for the World Health Organization, which asked him to help them find a way to reduce deaths in surgery."
The Johns Hopkins Bloomberg School of Public Health announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation. Alain Labrique, PhD, director of the Johns Hopkins University Global mHealth Initiative, will pursue an innovative global health and development research project, titled "mTIKKA - Harnessing a Mobile - Cloud System to Achieve Universal Vaccination."
As Liberia rebuilds a health care system decimated by the 2014 Ebola outbreak, understanding precisely how far citizens live from health facilities and its impact on seeking care can help shape new strategies to improve health care delivery and reduce geographic disparities.
Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today it was awarded a contract with the Biomedical Advanced Research and Development Authority (BARDA), for the research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident.
› Verified 8 days ago